Ultime notizie per AbbVie (NYSE:ABBV) Azioni

ABBVIE INC

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Jim Cramer

Equities

Markets

ABBV

L&#39;analisi sulle nuove dinamiche di mercato evidenzia le sfide per gli investitori tra sicurezza, volatilità e strategie di rendimento.

Obbligazioni vs. azioni: Jim Cramer spiega dove sono i rendimenti migliori

Biotech

News

Health Care

Contracts

Movers

Trading Ideas

General

Un accordo multimiliardario nel settore biotech fa volare il titolo in borsa: analizziamo i dettagli della partnership.

Impennata superiore al 110% per questo titolo oggi: cosa sta succedendo?

Long Ideas

Media

$BTC

COIN

CRNC

Durante il programma &#34;Mad Money Lightning Round&#34; della CNBC, Jim Cramer ha consigliato l’acquisto di AbbVie Inc. (NYSE:ABBV) affermando che si tratta di un &#34;gioiello&#34; e di un &#34;vincitore&#34;. Ha aggiunto: &#34;Non posso credere che il titolo sia sceso così tanto&#34;.

Jim Cramer: è tempo di fare cassa? Ecco la sua strategia

AbbVie Inc

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/30/final-trades-jpmorgan-meta-abbvie-and-gap.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown, CEO of Ritholtz Wealth Management, said he is staying long on JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), adding that the company has the greatest <a href="https://www.benzinga.com/quote/JPM">CEO ever in banking</a>.
Supporting his views, several analysts, including, Baird, Morgan Stanley, RBC Capital, Piper Sandler and TD Securities, raised their price targets on the stock on May 20.
Kevin Simpson, Capital Wealth Planning CIO, said Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has tons of free cash flow.
As per recent news, Meta and Palmer Luckey-led defense tech startup Anduril Industries announced a partnership to develop rugged VR/AR headsets for the U.S. Army on May 29.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners named AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) as his final trade.
On May 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie's Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy.
Stephanie Link, Hightower chief investment strategist, picked The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) as her final trade.
Supporting her view, Gap reported quarterly earnings of 51 cents per share on May 29, beating the consensus estimate of 45 cents. Quarterly revenue came in at $3.46 billion, beating the Street estimate of $3.42 billion.
Price Action:
<ul class="wp-block-list">
<li>JPMorgan shares fell 0.1% to close at $264.00 on Friday.</li>
<li>Meta gained 0.4% to close at $647.49 on Friday.</li>
<li>AbbVie shares rose 0.3% to settle at $186.11 during the session.</li>
<li>Gap shares dipped 20.2% to close at $22.31 on Friday.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Large Cap

Meta, JPMorgan, Gap And A Health Care Stock On CNBC's 'Final Trades'

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$55.00</td>
<td>$71.1K</td>
<td>2.1K</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$25.00</td>
<td>$68.0K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$100.00</td>
<td>$44.0K</td>
<td>1.1K</td>
<td>960</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$630.00</td>
<td>$119.6K</td>
<td>6</td>
<td>705</td>
</tr>
<tr>
<td>VEEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$210.00</td>
<td>$65.7K</td>
<td>534</td>
<td>589</td>
</tr>
<tr>
<td>NVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$115.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>379</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$80.00</td>
<td>$42.5K</td>
<td>883</td>
<td>372</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$295.00</td>
<td>$40.2K</td>
<td>985</td>
<td>344</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$195.00</td>
<td>$25.8K</td>
<td>5.0K</td>
<td>319</td>
</tr>
<tr>
<td>COR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$280.00</td>
<td>$36.4K</td>
<td>762</td>
<td>200</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a put option sweep that happens to be bearish, expiring in 51 day(s) on July 18, 2025. This event was a transfer of 89 contract(s) at a $55.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $71.1K, with a price of $799.0 per contract. There were 2196 open contracts at this strike prior to today, and today 1320 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 1000 contract(s) at a $25.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $68.0K, with a price of $68.0 per contract. There were 2289 open contracts at this strike prior to today, and today 1083 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a put option trade that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 958 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $46.0 per contract. There were 1139 open contracts at this strike prior to today, and today 960 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with neutral sentiment. It expires in 51 day(s) on July 18, 2025. Parties traded 46 contract(s) at a $630.00 strike. The total cost received by the writing party (or parties) was $119.6K, with a price of $2600.0 per contract. There were 6 open contracts at this strike prior to today, and today 705 contract(s) were bought and sold. 
• Regarding VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we observe a put option sweep with bearish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 212 contract(s) at a $210.00 strike. This particular put needed to be split into 45 different trades to become filled. The total cost received by the writing party (or parties) was $65.7K, with a price of $310.0 per contract. There were 534 open contracts at this strike prior to today, and today 589 contract(s) were bought and sold. 
• For NVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), we notice a call option sweep that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 224 contract(s) at a $115.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $125.0 per contract. There were 1879 open contracts at this strike prior to today, and today 379 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option trade that happens to be bearish, expiring in 79 day(s) on August 15, 2025. This event was a transfer of 100 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $42.5K, with a price of $425.0 per contract. There were 883 open contracts at this strike prior to today, and today 372 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 134 contract(s) at a $295.00 strike. The total cost received by the writing party (or parties) was $40.2K, with a price of $300.0 per contract. There were 985 open contracts at this strike prior to today, and today 344 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 137 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $189.0 per contract. There were 5038 open contracts at this strike prior to today, and today 319 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a put option sweep with neutral sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 135 contract(s) at a $280.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $36.4K, with a price of $270.0 per contract. There were 762 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

GILD

MRNA

REGN

VEEV

10 Health Care Stocks Whale Activity In Today's Session

Today, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.scri.com%2F&amp;esheet=54261017&amp;newsitemid=20250528690522&amp;lan=en-US&amp;anchor=Sarah+Cannon+Research+Institute+%28SCRI%29&amp;index=1&amp;md5=89e1c577df921146fbc6b00973e49a5c">Sarah Cannon Research Institute (SCRI)</a>, one of the world's leading oncology research organizations conducting community-based clinical trials, announced a strategic alliance with AbbVie. The alliance aims to accelerate the development of innovative therapies for patients with cancer through collaborative scientific engagement and operational synergies to enhance the delivery of clinical trials.
 &nbsp;

Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie To Advance Cancer Therapies

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/30/25</td>
<td>$65.00</td>
<td>$37.4K</td>
<td>872</td>
<td>1.6K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$302.0K</td>
<td>5.1K</td>
<td>1.1K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$850.00</td>
<td>$33.5K</td>
<td>31.4K</td>
<td>798</td>
</tr>
<tr>
<td>VERA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$30.00</td>
<td>$41.1K</td>
<td>446</td>
<td>342</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$400.00</td>
<td>$33.4K</td>
<td>1.9K</td>
<td>282</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$65.00</td>
<td>$104.7K</td>
<td>114</td>
<td>162</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$180.00</td>
<td>$111.8K</td>
<td>2.1K</td>
<td>105</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$215.00</td>
<td>$54.2K</td>
<td>385</td>
<td>87</td>
</tr>
<tr>
<td>VRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$80.00</td>
<td>$28.8K</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>ONC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$220.00</td>
<td>$32.2K</td>
<td>0</td>
<td>15</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a put option trade with neutral sentiment. It expires in 3 day(s) on May 30, 2025. Parties traded 170 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $37.4K, with a price of $220.0 per contract. There were 872 open contracts at this strike prior to today, and today 1645 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a put option trade that happens to be bearish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 1000 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $302.0K, with a price of $302.0 per contract. There were 5187 open contracts at this strike prior to today, and today 1108 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $850.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $33.5K, with a price of $335.0 per contract. There were 31403 open contracts at this strike prior to today, and today 798 contract(s) were bought and sold. 
• For VERA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), we notice a put option sweep that happens to be bullish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 34 contract(s) at a $30.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $41.1K, with a price of $1210.0 per contract. There were 446 open contracts at this strike prior to today, and today 342 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 598 day(s) on January 15, 2027. This event was a transfer of 10 contract(s) at a $400.00 strike. The total cost received by the writing party (or parties) was $33.4K, with a price of $3342.0 per contract. There were 1906 open contracts at this strike prior to today, and today 282 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option sweep that happens to be bullish, expiring in 570 day(s) on December 18, 2026. This event was a transfer of 161 contract(s) at a $65.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $104.7K, with a price of $655.0 per contract. There were 114 open contracts at this strike prior to today, and today 162 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option trade with bearish sentiment. It expires in 80 day(s) on August 15, 2025. Parties traded 87 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $111.8K, with a price of $1286.0 per contract. There were 2152 open contracts at this strike prior to today, and today 105 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option sweep with bullish sentiment. It expires in 24 day(s) on June 20, 2025. Parties traded 67 contract(s) at a $215.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $810.0 per contract. There were 385 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
• For VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 40 contract(s) at a $80.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $720.0 per contract. There were 50 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold. 
• For ONC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), we notice a call option trade that happens to be neutral, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 15 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $2150.0 per contract. There were 0 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VERA

VRNA

AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock is trending on Tuesday after the U.S. drug giant announced that key data from its broad oncology portfolio will be showcased at the upcoming American Society of Clinical <a href="https://www.benzinga.com/pressreleases/25/05/n45616821/abbvie-features-new-data-across-difficult-to-treat-solid-tumors-and-blood-cancers-at-asco-2025-hig" target="_blank" rel="noreferrer noopener">Oncology (ASCO) Annual Meeting</a>.
An oral presentation on investigational&nbsp;elotuzumab adizutecan (ABBV-400, Temab-A), a next-generation, c-Met directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">payload, will showcase</a>:
<ul class="wp-block-list">
<li>Preliminary safety and efficacy results from the dose expansion part of a Phase 1 study in 41 patients with pre-treated, advanced epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC).</li>
<li>The objective response rate (ORR) was 63%. High ORR was observed regardless of c-Met protein expression levels.</li>
<li>At the time of data cut-off, 54% of responders experienced a ≥6 months duration of response (DoR).</li>
<li>Temab-A is also being evaluated in multiple ongoing&nbsp;clinical trials, including: 
<ul class="wp-block-list">
<li>Phase 1/2 Study in first-line NSCLC without actionable&nbsp;genomic alterations in combination with budigalimab.</li>
<li>Phase 2 study in second-line metastatic colorectal cancer (CRC) in combination with fluorouracil, folinic acid, and bevacizumab.</li>
<li>Phase 3 study as monotherapy in patients with c-Met overexpressing refractory metastatic&nbsp;CRC.</li>
</ul>
</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45418687/fda-fast-tracks-abbvies-new-lung-cancer-therapy-emrelis-for-tough-lung-cancer-cases" rel="noreferrer noopener">FDA Fast-Tracks AbbVie&#8217;s New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases</a>
Additional oral presentations will highlight new safety and efficacy data for ABBV-706, a SEZ6-directed ADC with a Top1i payload, and pivekimab sunirine&nbsp;(PVEK), a novel ADC designed to target CD123:
<ul class="wp-block-list">
<li>In a Phase 1 open-label study of ABBV-706 monotherapy, 64 patients received ABBV-706 monotherapy IV at 1.3–3.5 mg/kg once every 3 weeks.</li>
<li>The entire cohort had an ORR of 31.3% and a median DoR of 5.6 months.</li>
<li>This ongoing study is evaluating ABBV-706 as monotherapy or in combination with budigalimab, carboplatin, or cisplatin in patients with advanced solid tumors expressing SEZ6, including small-cell lung cancer, NENs, and high-grade Central Nervous System tumors.</li>
</ul>
Results from the open-label, multicenter Phase&nbsp;1b/2 CADENZA trial of PVEK monotherapy in patients with previously untreated or relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a highly aggressive and rare type of blood cancer, demonstrated clinical benefit.
<ul class="wp-block-list">
<li>The results show that among 33 untreated patients, the primary endpoint of composite complete response (CCR) rate, defined as CR + clinical CR (CR with minimal skin abnormality), was 70%, with a median duration of CCR of 9.8 months.</li>
<li>ORR was 85%.</li>
<li>In the 51 patients, the CCR rate was 14%, with a median duration of CCR of 9.2 months. ORR was 35%.</li>
<li>PVEK is also being evaluated in a Phase 1/2 study in R/R and newly diagnosed acute myeloid leukemia.</li>
</ul>
Price Action: At the last check on Tuesday, ABBV stock was up 1.11% at $185.29 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45616623/temu-parent-pdd-does-not-mention-tariffs-impact-blames-external-environment-and-ecosystem-investments-for-profit-plunge" target="_blank" rel="noreferrer noopener">Temu Parent PDD Does Not Mention Tariffs Impact, Blames &#8216;External Environment&#8217; And &#8216;Ecosystem Investments&#8217; For Profit Plunge</a></li>
</ul>
Image: Shtutterstock

AbbVie To Present Cancer Trial Data At Upcoming ASCO Event

-&nbsp; &nbsp;&nbsp;Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer (NSCLC), ABBV-706 in high-grade neuroendocrine neoplasms (NENs) and pivekimab sunirine (PVEK) in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
NORTH CHICAGO, Ill., May 27, 2025 /PRNewswire/ -- AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3, 2025). These new data highlight significant progress in AbbVie's robust oncology pipeline, across a range of difficult-to-treat solid tumors and blood cancers.

AbbVie Says Key Data From Broad Oncology Portfolio To Be Showcased Across Multiple Oral Presentations And Posters At 2025 ASCO Annual Meeting

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$90.00</td>
<td>$286.6K</td>
<td>20.5K</td>
<td>19.1K</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$320.00</td>
<td>$82.5K</td>
<td>2.3K</td>
<td>5.2K</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$290.00</td>
<td>$330.7K</td>
<td>64</td>
<td>1.3K</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$50.00</td>
<td>$81.0K</td>
<td>573</td>
<td>292</td>
</tr>
<tr>
<td>OCUL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$10.00</td>
<td>$32.5K</td>
<td>60</td>
<td>190</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$810.00</td>
<td>$35.5K</td>
<td>12</td>
<td>169</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$45.00</td>
<td>$43.0K</td>
<td>3.5K</td>
<td>113</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$60.00</td>
<td>$35.0K</td>
<td>2.4K</td>
<td>85</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$175.00</td>
<td>$93.8K</td>
<td>384</td>
<td>59</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$40.00</td>
<td>$29.9K</td>
<td>776</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option trade that happens to be bearish, expiring in 31 day(s) on June 20, 2025. This event was a transfer of 11467 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $286.6K, with a price of $25.0 per contract. There were 20532 open contracts at this strike prior to today, and today 19153 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option trade with bearish sentiment. It expires in 10 day(s) on May 30, 2025. Parties traded 60 contract(s) at a $320.00 strike. The total cost received by the writing party (or parties) was $82.5K, with a price of $1375.0 per contract. There were 2315 open contracts at this strike prior to today, and today 5276 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bullish sentiment. It expires in 10 day(s) on May 30, 2025. Parties traded 1350 contract(s) at a $290.00 strike. The total cost received by the writing party (or parties) was $330.7K, with a price of $245.0 per contract. There were 64 open contracts at this strike prior to today, and today 1371 contract(s) were bought and sold. 
• Regarding AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we observe a call option sweep with bullish sentiment. It expires in 31 day(s) on June 20, 2025. Parties traded 270 contract(s) at a $50.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $81.0K, with a price of $300.0 per contract. There were 573 open contracts at this strike prior to today, and today 292 contract(s) were bought and sold. 
• Regarding OCUL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>), we observe a put option trade with bearish sentiment. It expires in 213 day(s) on December 19, 2025. Parties traded 100 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $32.5K, with a price of $325.0 per contract. There were 60 open contracts at this strike prior to today, and today 190 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bearish, expiring in 38 day(s) on June 27, 2025. This event was a transfer of 24 contract(s) at a $810.00 strike. The total cost received by the writing party (or parties) was $35.5K, with a price of $1480.0 per contract. There were 12 open contracts at this strike prior to today, and today 169 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a put option trade with bearish sentiment. It expires in 304 day(s) on March 20, 2026. Parties traded 104 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $414.0 per contract. There were 3563 open contracts at this strike prior to today, and today 113 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with neutral sentiment. It expires in 87 day(s) on August 15, 2025. Parties traded 25 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1400.0 per contract. There were 2475 open contracts at this strike prior to today, and today 85 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 87 day(s) on August 15, 2025. Parties traded 59 contract(s) at a $175.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $93.8K, with a price of $1590.0 per contract. There were 384 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bullish, expiring in 605 day(s) on January 15, 2027. This event was a transfer of 9 contract(s) at a $40.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $29.9K, with a price of $3330.0 per contract. There were 776 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKRO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OCUL

10 Health Care Stocks With Whale Alerts In Today's Session

On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to those seen abroad.
At a media event, Trump told reporters he was aiming for price cuts of between 59% and 90% and gave drug companies 30 days to play ball.
Wall Street digested the news, and while major biopharma stocks saw share prices drop the day the EO was announced, most industry stocks rebounded.&nbsp;
Here are three pharma stocks that won&#8217;t just rebound, but are poised to soar because of Trump&#8217;s executive order.
<h1 class="wp-block-heading">Team Trump on Solid Ground?</h1>
Nobody&#8217;s denying that US drug prices are out of whack. A 2024 RAND Corporation study concluded US drug prices were approximately three times higher than those in 33 other developed countries.
Presidents have full power to order such a price cut from a private industry, at least in part.
&#8220;That&#8217;s especially the case in sectors like healthcare where government programs like Medicare are massive buyers,&#8221; said Lou Carter, founder and CEO at the Best Practice Institute in Palm Beach Gardens, Fla. &#8220;Policy isn&#8217;t just about law—it&#8217;s about leverage. This EO uses the weight of public programs to force pricing accountability, and that&#8217;s smart business when you&#8217;re managing taxpayer funds.&#8221;
Congress and the courts can try to stop the EO in its tracks, but success on that front is unlikely.&nbsp;
&#8220;Politically, it&#8217;s tough to argue against lower drug prices,&#8221; Carter said. &#8220;Even if pharma lobbies hard, most lawmakers know it&#8217;s political suicide to oppose something that helps seniors afford insulin. If this goes to court, it&#8217;ll hinge on procedural questions—not on whether the move is popular or right.&#8221;
<h1 class="wp-block-heading">Bigger Drug Makers are Hardest Hit</h1>
Given the size and scope of the EO, it&#8217;s no surprise that the more substantial drug companies may find themselves in financial trouble.&nbsp;
&#8220;Large-cap biotech and specialty pharma companies with heavy Medicare exposure like Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) or Regeneron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) could be hit hardest,&#8221; said Dr. Will Soliman, Founder and CEO of the New York City-based Accreditation Council for Medical Affairs. &#8220;They rely on high-margin (Medicare) Part B drugs.&#8221;
Vertical-oriented drug makers could also feel the heat from the EO.&nbsp;
&#8220;Specialized oncology manufacturers like Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) have greater exposure than diversified pharmaceutical companies with broader portfolio ranges,&#8221; said Seann Malloy, founder and managing partner of Malloy Law Offices in Bethesda, Md. &#8220;Small to mid-cap biotechnology companies with early commercial products often fall outside immediate impact zones due to limited Medicare utilization and existing price protection provisions. &#8220;
&#8220;The executive order&#8217;s key element mandates that Medicare&#8217;s prescription drug payments align with the lowest prices in other developed countries, essentially using international reference pricing,&#8221; Malloy said. &#8220;While some demonstration projects will start within 30 days, full implementation across all provisions will take longer, likely 6-12 months, due to necessary regulatory development. &#8220;
Timing could play a big role in determining how much of an impact the EO will have on biotech drug stocks, if any.
Initially, the order focuses on physician-administered drugs under Medicare Part B but may later include retail prescriptions under Part D. &#8220;This staged implementation means the immediate and long-term market effects will differ, a point often missed by investors,&#8221; Malloy noted. &#8220;Despite initial impressions of swift price changes, significant revenue impacts will likely be delayed by extensive regulatory procedures.&#8221;
Additionally, overseas drug providers may face stiff headwinds from the Trump drug price directive.
&#8220;International manufacturers are most vulnerable,&#8221; said Javier Palomarez, founder and CEO of the United States Hispanic Business Council. &#8220;Many of them ship to the United States because of the return on investment &#8211; eroding that return dampens the incentive and ability to ship medicines across the world, which could lead to total loss of US market access for some companies.&#8221;
<h1 class="wp-block-heading">Three Drug Stocks That Bear Watching Over the Next 30 Days</h1>
Biotech investors looking to leverage the Trump EO should understand Trump&#8217;s intention to &#8220;cut out the middleman,&#8221; as he said in his May 12 press event. This translates to good news for actual drug manufacturers and not-so-good news for so-called pharmacy-benefit managers.
PBM&#8217;s act as intermediaries between health insurance companies, big employers, drug manufacturers, insurers, and patients. While they don&#8217;t produce prescription drugs, they handle the more mundane side of the drug business, like claims processing and negotiating prescription drug prices.
The big drug producers have historically blamed the PBMs for sky-high drug prices and would likely back any initiative that expands the direct-to-consumer drug marketplace. In that scenario, no insurers are needed, as drug consumers could deal directly with drug manufacturers to buy the medicines they need, presumably at a more affordable price.
Investors in that marketplace would want large drug makers, and big PBMs would not. These three drug stocks stand out on the plus side.
<h2 class="wp-block-heading">Eli Lilly</h2>
Drug manufacturing giant Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is priced high at $730 per share, but it&#8217;s a stock that would likely prosper in a direct-to-consumer prescription drug marketplace. The stock is off by 5.0% year-to-date, but 26 Wall Street analysts who track LLY give it a top rating. The company&#8217;s recent earnings per share are off the charts, with an upward spike of 106% in EPS in 2024 and an estimated 68% in 2025. The stock is off 20% compared to recent highs, which could mean a nice discount for a drug industry stalwart.
<h2 class="wp-block-heading">Novo Nordisk</h2>
Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has experienced market woes that preceded the Trump E/O, as competitors continue to chew into market share in the lucrative weight loss drug market. Particularly damaging was a recent study that concluded patients taking Eli Lilly&#8217;s Zepbound were losing weight faster than with Novo&#8217;s Wegovy. That&#8217;s one big reason Novo Nordisk has seen its share price fall by 50% over the past year. Yet the stock is in rebound mode right now, up 13.9% over the past month. A $2.2 billion deal between Novo and Septerna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) to develop weight loss pills is seen as a big step by analysts and big names like Goldman Sachs and JP Morgan are sticking to their buy calls on the stock. Meanwhile, a larger group of industry analysts is out with a consensus 50% share price upside from current levels.
<h2 class="wp-block-heading">AbbVie</h2>
AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is a genuine cash flow producer that seems immune to any political interference from Washington, D.C. The drug manufacturer has a diverse set of popular prescription drugs, like Botox, Humira, Rinvoq, and Skyrizi. The stock only fell by a paltry 1% on the E news this week, and is up 5% over the past month. It also comes with a healthy 3.6% dividend for income-minded investors, a robust drug pipeline in play, and a brand new regulatory &#8220;green light&#8221; for its lung cancer drug Emrelis, supporting the rationale that ABBV shares should continue to climb in 2025.
<a href="https://benzinga.zoom.us/webinar/register/WN_OJ2FBspHSJSSVNlW8zGapw/?utm_campaign=webinar052025&amp;utm_adType=sponsorad&amp;utm_ad=RD051925/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">Smart Options Plays for Traders Watching Junk Bonds</a> Credit markets are breaking down. Volatility is back. Join Ryan Faloona, Anne-Marie Baiynd, and Tim Melvin live on May 20 at 6 PM ET to see how seasoned traders are using junk bond signals and short-term options to hedge, profit, and stay a step ahead. <a href="https://benzinga.zoom.us/webinar/register/WN_OJ2FBspHSJSSVNlW8zGapw/?utm_campaign=webinar052025&amp;utm_adType=sponsorad&amp;utm_ad=RD051925/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">Save your seat for this live tactical session.</a>
Image via Shutterstock

Opinion

SEPN

3 Stocks That Will Profit From Trump's Drug Price Cut

<h2 class="wp-block-heading">Pfizer's Oncology Transformation: Why This Beaten-Down Pharma Giant Is Poised For A Strong Comeback</h2>
Despite trading near decade-low valuations, Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen acquisition. While the market remains fixated on COVID-related revenue declines and upcoming patent cliffs, investors are overlooking the company's dramatically expanded oncology pipeline, robust free cash flow, and the potential for multiple catalysts in 2025-2026 that could drive significant share price appreciation.
<h2 class="wp-block-heading"><a>Key Points:</a></h2>
<ol class="wp-block-list">
<li>Pfizer's current valuation metrics reveal a striking disconnect with its long-term growth potential</li>
<li>The $43 billion Seagen acquisition has fundamentally transformed Pfizer's oncology pipeline</li>
<li>Despite near-term revenue pressures, Pfizer's financial position remains strong with multiple pathways to growth</li>
<li>A comparison with key competitors shows Pfizer offers compelling risk-reward at current prices</li>
<li>Upcoming catalysts in 2025-2026 could trigger significant revaluation</li>
</ol>
<h2 class="wp-block-heading"><a>Introduction: The Fall From Grace</a></h2>
Few pharmaceutical giants have experienced as dramatic a fall from grace as Pfizer. After riding high on the success of its COVID-19 vaccine and antiviral treatments in 2021-2022, the company has seen its stock price plummet over 60% from its December 2021 high of $52.61. At its current price of approximately $23.87, Pfizer trades at a P/E ratio of just 7.41, a level typically reserved for companies facing existential threats rather than one of the world's premier pharmaceutical innovators.
The market narrative surrounding Pfizer has been overwhelmingly negative, focused on:
<ol class="wp-block-list">
<li>The rapid decline of COVID-19 product revenues</li>
<li>Upcoming patent expirations for key drugs like Inlyta (2025) and Xtandi (2027)</li>
<li>Underwhelming pipeline developments in areas like weight loss</li>
<li>Concerns about the return on investment from the $43 billion Seagen acquisition</li>
</ol>
This pessimistic outlook has created what I believe is one of the most compelling investment opportunities in the pharmaceutical sector today. The market is dramatically undervaluing Pfizer's strategic transformation and the potential of its expanded oncology portfolio.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="975" height="609" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3.png" alt="" class="wp-image-12977" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3-768x480.png 768w" sizes="(max-width: 975px) 100vw, 975px" /></figure>
<h2 class="wp-block-heading"></h2>
<h2 class="wp-block-heading">&nbsp;Valuation Disconnect: A Market Overreaction</h2>
Pfizer's current valuation metrics tell a compelling story of market overreaction:
<ul class="wp-block-list">
<li>P/E Ratio: 7.41x (vs. industry average of ~15x)</li>
<li>Forward P/E: 8.0x (based on 2025 guidance)</li>
<li>Dividend Yield: 7.20% (substantially higher than its historical average)</li>
<li>Market Cap: $135.38 billion (down from over $300 billion at its peak)</li>
</ul>
When a company of Pfizer's caliber trades at these valuation levels, either the market is correctly anticipating a permanent deterioration in business fundamentals, or it's presenting a significant opportunity for contrarian investors. I believe it's the latter.
While Pfizer's revenue and earnings did experience a sharp decline following the normalization of COVID-19 product demand, the company's 2025 guidance suggests stabilization is at hand. For 2025, Pfizer projects:
<ul class="wp-block-list">
<li>Revenue between $61-64 billion</li>
<li>Adjusted EPS of $2.80-3.00</li>
<li>Operational revenue growth of 0-5% (excluding non-recurring COVID revenue)</li>
</ul>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="975" height="609" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4.png" alt="" class="wp-image-12979" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4-768x480.png 768w" sizes="(max-width: 975px) 100vw, 975px" /></figure>
These projections, while not spectacular, hardly justify a valuation typically reserved for businesses in secular decline. More importantly, they provide a stable foundation from which Pfizer's oncology transformation can drive future growth.
<h2 class="wp-block-heading"><a>The Seagen Acquisition: A Pipeline Revolution</a></h2>
In December 2023, Pfizer completed its $43 billion acquisition of Seagen, a move that fundamentally transformed the company's oncology portfolio. This acquisition wasn't merely about adding incremental revenue; it represented a strategic pivot that doubled Pfizer's early-stage oncology pipeline and positioned the company as a leader in antibody-drug conjugate (ADC) technology—one of the most promising approaches in cancer treatment today.
The Seagen acquisition brought immediate and long-term benefits:
Immediate Portfolio Enhancement:
<ul class="wp-block-list">
<li>Four FDA-approved cancer drugs (Adcetris, Padcev, Tivdak, and Tukysa)</li>
<li>Combined revenues of approximately $2.2 billion in 2023</li>
<li>Pfizer projects these medicines could contribute over $10 billion in risk-adjusted revenues by 2030</li>
</ul>
Pipeline Transformation:
<ul class="wp-block-list">
<li>Doubled Pfizer's oncology pipeline to 60 programs</li>
<li>Expanded ADC technology platform</li>
<li>Added multiple late-stage pipeline candidates with blockbuster potential</li>
</ul>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="975" height="609" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5.png" alt="" class="wp-image-12980" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5-768x480.png 768w" sizes="(max-width: 975px) 100vw, 975px" /></figure>
This acquisition wasn't made out of desperation but from a position of strategic foresight. ADC technology, which Seagen pioneered, allows for more precise targeting of cancer cells while sparing healthy tissue. This approach is increasingly seen as the future of cancer treatment, with the global ADC market projected to grow at a CAGR of over 10% through 2030.
Pfizer CEO Albert Bourla's comment that "We are not acquiring the golden eggs. We are acquiring the goose that laid the golden eggs" captures the strategic rationale perfectly. The long-term value lies not just in current products but in Seagen's innovation engine.
<h2 class="wp-block-heading"><a>Financial Strength Despite Headwinds</a></h2>
While near-term revenue pressures are real, Pfizer's financial position remains remarkably strong:
Q1 2025 Performance:
<ul class="wp-block-list">
<li>Revenue of $13.72 billion</li>
<li>Adjusted EPS of $0.92 (significantly above analyst expectations of $0.66)</li>
<li>Maintained full-year guidance despite external challenges</li>
</ul>
Balance Sheet Strength:
<ul class="wp-block-list">
<li>Substantial cash flow generation</li>
<li>Dividend well-covered by earnings</li>
<li>Continued cost optimization (targeting $7.7 billion in savings by 2027)</li>
</ul>
In its Q1 2025 earnings call, Pfizer's management noted they are "trending towards the upper end" of their adjusted EPS guidance range for 2025, suggesting operational efficiency and cost discipline are bearing fruit.
<h2 class="wp-block-heading"><a>Competitive Landscape: How Pfizer Stacks Up</a></h2>
To fully appreciate Pfizer's investment potential, we need to compare it to major competitors:
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="975" height="609" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6.png" alt="" class="wp-image-12981" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6-768x480.png 768w" sizes="(max-width: 975px) 100vw, 975px" /></figure>
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>):
<ul class="wp-block-list">
<li>Market Cap: ~$395 billion</li>
<li>P/E Ratio: ~25x</li>
<li>Dividend Yield: ~3.0%</li>
<li>Growth Challenges: Facing Stelara patent expiration in 2025 and ongoing talc litigation</li>
</ul>
Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>):
<ul class="wp-block-list">
<li>Market Cap: ~$208 billion</li>
<li>P/E Ratio: ~16x</li>
<li>Dividend Yield: ~2.9%</li>
<li>Growth Challenges: Heavy reliance on Keytruda, which faces patent expiration later this decade</li>
</ul>
AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>):
<ul class="wp-block-list">
<li>Market Cap: ~$340 billion</li>
<li>P/E Ratio: ~20x</li>
<li>Dividend Yield: ~3.6%</li>
<li>Growth Challenges: Recovering from Humira patent cliff through Skyrizi and Rinvoq growth</li>
</ul>
Compared to these peers, Pfizer offers significantly more attractive valuation metrics while facing similar industry-wide challenges. The valuation gap implies the market believes Pfizer's growth prospects are substantially worse than its competitors, an assumption not supported by the company's pipeline and strategic initiatives.
<h2 class="wp-block-heading"><a>Catalysts for Revaluation in 2025-2026</a></h2>
Several potential catalysts could drive a significant revaluation of Pfizer in the next 12-24 months:
<ol class="wp-block-list">
<li>Pipeline Milestones: Multiple late-stage readouts, particularly from oncology programs, are expected in 2025-2026, including data from the promising disitamab vedotin program for bladder cancer.</li>
<li>Margin Expansion: Pfizer's cost optimization initiatives are projected to deliver $7.7 billion in savings by 2027, potentially lifting adjusted operating margins.</li>
<li>Oncology Revenue Growth: The oncology portfolio, particularly the former Seagen products, is projected to deliver strong growth as new indications are approved and commercial execution improves.</li>
<li>GLP-1 Program Advancement: Progress with danuglipron, Pfizer's oral GLP-1 candidate, could position the company in the rapidly growing obesity market.</li>
<li>Potential Divestments or Spin-offs: Strategic portfolio optimization could unlock shareholder value, with non-core assets potentially being divested.</li>
</ol>
<h2 class="wp-block-heading"><a>Investment Risks</a></h2>
No investment thesis is complete without acknowledging risks:
<ol class="wp-block-list">
<li>Patent Cliff Pressures: Pfizer faces patent expirations for Inlyta (2025) and Xtandi (2027), which will impact revenue in the near term.</li>
<li>Seagen Integration Challenges: Realizing the full potential of the Seagen acquisition depends on successful integration and pipeline execution.</li>
<li>Pharmaceutical Pricing Pressure: The Inflation Reduction Act and potential future drug pricing reforms could impact profitability.</li>
<li>Competition in Oncology: The oncology space is highly competitive, with many companies pursuing similar targets.</li>
<li>Tariff Uncertainties: As noted in recent earnings calls, potential pharmaceutical tariffs create uncertainty.</li>
</ol>
However, at current valuation levels, much of this risk appears to be already priced into the stock, creating an asymmetric risk-reward profile.
<h2 class="wp-block-heading">Conclusion: The Case for Pfizer's Resurgence</h2>
Pfizer's dramatic fall from grace has created a compelling opportunity for patient investors. The company's strategic pivot to oncology, particularly through the Seagen acquisition, has positioned it at the forefront of one of the most promising areas in medicine. While near-term challenges are real, the current valuation reflects an overly pessimistic view that fails to account for Pfizer's pipeline potential and strategic transformation.
With multiple catalysts on the horizon and a dividend yield providing substantial income while waiting for the investment thesis to play out, Pfizer offers one of the most attractive risk-reward profiles in the pharmaceutical sector today.
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare opportunity to acquire a premier pharmaceutical innovator at a deep discount to its intrinsic value.
Image Credit: Generated Using AI

Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025

Jim Cramer thinks that the bond market now offers a clearer risk-reward trade-off than so-called "safety" stocks, warning that rising 10-year Treasury yields and a political "wild card" in Washington make even dividend stalwarts feel shaky.
What Happened: The 10-year Treasury yield's jump to its highest level in more than a month has tightened the spread between bond payouts and blue-chip dividends, dulling the appeal of AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) and Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), Cramer <a href="https://www.cnbc.com/2025/05/14/jim-cramer-explains-why-its-hard-to-own-usual-safety-stocks-here.html">told</a> CNBC&#8217;s &#8216;Mad Money&#8217; viewers on Wednesday.
"In a very uncertain tape for what <a href="https://www.benzinga.com/content/44809259/3-safe-dividend-stocks-as-investors-seek-to-reset-diversification">used to be called</a> ‘safety stocks,' I'd rather just own a piece of paper like the 10-year Treasury, where, if worst comes to worst, at least I get my money back," Cramer said.
Cramer flagged Robert F. Kennedy Jr., newly installed as Health and Human Services secretary, as an <a href="https://www.benzinga.com/markets/equities/24/11/42254495/trumps-hhs-pick-rfk-jr-has-a-long-history-of-challenging-global-health-policies">unpredictable force</a> who could clamp down on pharmaceutical pricing and food additives. "Investors don't know whether Kennedy will act in favor of the companies he's tasked with regulating," he cautioned.
See also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45426516/chuck-schumer-says-trump-is-letting-cartel-members-into-the-us-asks-how-much-memecoin-did-they-pay">Chuck Schumer Says Trump Is &#8216;Letting Cartel Members&#8217; Into The US, Asks How Much &#8216;Memecoin&#8217; Did They Pay</a>
What To Know: That uncertainty compounds existing headaches. Johnson &amp; Johnson is <a href="https://www.benzinga.com/general/biotech/25/04/44586129/us-judge-rejects-another-johnson-johnson-attempt-to-use-bankruptcy-for-talc-cancer-claims">still wrestling</a> with talc-related lawsuits that have already cost billions in settlements and reserves, a cloud Wall Street <a href="https://www.benzinga.com/25/04/44920880/expert-flags-never-before-observed-trio-falling-stocks-and-short-yields-bucking-rising-long-yields-nothing-is-normal-about-this">fears could grow</a> heavier if bond yields <a href="https://www.benzinga.com/25/05/45399783/gordon-johnson-warns-of-potential-liberation-day-20-as-30-year-treasury-yields-approach-5-amid-dollar-weakness?utm_source=chatgpt.com">keep luring</a> income-seekers away. AbbVie's rich dividend likewise looks less generous when a risk-free Treasury pays nearly the same rate with zero headline risk.
Consumer staples aren't immune either, says Cramer. Procter &amp; Gamble and Colgate boast recession-proof brands, yet their 2–3% yields no longer tower over Treasuries, and Cramer said "the yields may simply not be high enough to justify the risk."
Snack titan PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) and cereal maker General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) could also <a href="https://www.benzinga.com/government/regulations/24/11/42144709/kennedys-war-on-food-dyes-could-be-coming-to-your-breakfast-table">come under fire</a> if Kennedy pushes to restrict artificial colors and other additives, Cramer warned, asking rhetorically whether kids would still eat Lucky Charms without its rainbow marshmallows.
Why It Matters: For now, Cramer said he is "tempted to buy General Mills" on weakness, but fears Washington's next pitch more than the stock's upside.
Cramer also told "Mad Money" viewers that recession worries can be a buying opportunity, saying high-quality retailers look cheap so long as you don't think the economy will "fall off a cliff." Despite earlier warning, the sector was in the trade-war "blast radius," he now does have a <a href="https://www.benzinga.com/25/05/45416455/jim-cramer-says-these-retail-stocks-rl-gap-can-survive-a-market-correction">couple of clear favorites</a> to scoop up on any dip.
Benzinga Edge Stock Rankings indicate Johnson &amp; Johnson has a Momentum in the 47th percentile and Growth in the 63rd, how do other &#8220;safety&#8221; stocks rank in terms of these metrics? <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Check them out here</a>.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="442" height="282" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15010652/Screenshot-2025-05-15-at-14.06.33.png" alt="" class="wp-image-915950" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15010652/Screenshot-2025-05-15-at-14.06.33.png 442w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15010652/Screenshot-2025-05-15-at-14.06.33-300x191.png 300w" sizes="(max-width: 442px) 100vw, 442px" /></figure>
Photo courtesy: katz / Shutterstock.com
Read next: <a href="https://www.benzinga.com/general/travel/25/05/45427289/peter-schiff-warns-qatars-200-billion-boeing-deal-could-spike-us-inflation-interest-rates-says-treasury-sell-off-may-follow">Peter Schiff Warns Qatar&#8217;s $200 Billion Boeing Deal Could Spike US Inflation, Interest Rates — Says Treasury Sell-Off May Follow</a>

Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets

The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie&nbsp;Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Emrelis&nbsp;(telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">received a prior systemic therapy</a>.
High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45415840/u-s-fda-approves-emrelis-telisotuzumab-vedotin-tllv-for-adults-with-previously-treated-advanced-no" rel="noreferrer noopener">by an FDA-approved test</a>.
This indication is approved based on overall response rate (ORR) and duration of response (DOR).
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s), the company said in a statement on Wednesday.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45079377" rel="noreferrer noopener">AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis</a>
Emrelis is a c-Met-directed antibody-drug conjugate (ADC) and the first and only treatment approved for this patient population.&nbsp;
ADCs are designed to target unique biomarkers such as the c-Met protein and deliver a potent &#8216;payload&#8217; directly to the biomarker-expressing cell.
Data from the Phase 2 LUMINOSITY study, designed to characterize the efficacy and safety of EMRELIS in c-Met overexpressing advanced NSCLC populations, support the FDA&#8217;s accelerated approval.
Findings from the study showed patients with high c-Met protein overexpression (n=84) who received Emrelis demonstrated a 35% Overall Response Rate (ORR) and Duration of Response (DOR) with a median of 7.2 months.
In&nbsp;December 2021, the FDA granted EMRELIS&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4408820-1&amp;h=2952437730&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4264002-1%26h%3D3470428670%26u%3Dhttps%253A%252F%252Fnews.abbvie.com%252F2022-01-04-AbbVie-Announces-U-S-FDA-Granted-Breakthrough-Therapy-Designation-BTD-to-Telisotuzumab-Vedotin-Teliso-V-for-Previously-Treated-Non-Small-Cell-Lung-Cancer%26a%3DBreakthrough%2BTherapy%2BDesignation%2Bby%2Bthe%2BFDA&amp;a=Breakthrough+Therapy+Designation" rel="noreferrer noopener">Breakthrough Therapy Designation</a> (BTD) based on Phase 2 LUMINOSITY study data.
Emrelis is being further evaluated as a monotherapy in patients with previously treated c-Met overexpressing NSCLC in the randomized Phase 3 confirmatory global study&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4408820-1&amp;h=741691694&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04928846&amp;a=TeliMET+NSCLC-01" rel="noreferrer noopener">TeliMET NSCLC-01</a>.
Enrollment in the study is underway and continues across global clinical trial sites.
The FDA has also approved Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) VENTANA&nbsp;MET (SP44) RxDx Assay, the only IHC companion diagnostic identifying patients eligible for Emrelis treatment.
On Wednesday, AbbVie&nbsp;and ADARx Pharmaceuticals announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45405186/abbvie-and-adarx-pharmaceuticals-announce-collaboration-and-license-option-agreement-to-develop-ne" rel="noreferrer noopener">immunology, and oncology</a>.
siRNA represents a class of molecules capable of regulating gene expression and protein production. Unlike traditional modalities such as antibodies and small molecules, siRNA regulates gene expression. These molecules are designed to prevent the production of disease-causing proteins by targeting the messenger RNA (mRNA) that encodes for such proteins.
ADARx will receive a&nbsp;$335 million&nbsp;upfront payment and is eligible to receive several billion dollars in additional contingent payments, including option-related fees, milestone payments, and royalties.
Price Action: ABBV stock is down 5.32% at $177.96&nbsp;at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45416148/pony-ai-shares-rise-after-report-of-confidential-hong-kong-ipo-to-fund-robotaxi-expansion" target="_blank" rel="noreferrer noopener">Robotaxi Service Pony AI Stock Falls Despite IPO Buzz &#8211; Here&#8217;s Why</a></li>
</ul>
Photo via Shutterstock

RHHBY

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases

WIIM

AbbVie shares are trading lower after Citigroup downgraded the stock from Buy to Neutral and lowered its price target from $210 to $205.

AbbVie Announces That EMRELIS Has Been Granted Accelerated Approval By The FDA For The Treatment Of Adult Patients With Locally Advanced Or Metastatic, Non-Squamous Non-Small Cell Lung Cancer With High C-Met Protein Overexpression  Who Have Received A Prior Systemic Therapy

During the last three months, 10 analysts shared their evaluations of AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $219.8, along with a high estimate of $250.00 and a low estimate of $194.00. Marking an increase of 1.52%, the current average surpasses the previous average price target of $216.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747227667_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of AbbVie's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$216.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$210.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$214.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$241.00</td>
<td>$239.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$194.00</td>
<td>-</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AbbVie. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of AbbVie compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into AbbVie's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABBV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AbbVie analyst ratings.</a>
<h2>About AbbVie</h2>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>A Deep Dive into AbbVie's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: AbbVie's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 8.39%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AbbVie's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 9.56%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AbbVie's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 53.78% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): AbbVie's ROA stands out, surpassing industry averages. With an impressive ROA of 0.94%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 49.22, AbbVie faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: AbbVie Through The Eyes Of 10 Analysts

Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies across neuroscience, immunology and oncology
NORTH CHICAGO, Ill. and SAN DIEGO, May 14, 2025 /PRNewswire/ --&nbsp;AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.
siRNA represents a class of molecules capable of regulating gene expression and protein production. Unlike traditional modalities such as antibodies and small molecules, siRNA regulates the expression of genes. These molecules are designed to prevent the production of disease-causing proteins by targeting the messenger RNA (mRNA) that encodes for such proteins.
The strategic collaboration will leverage ADARx's RNA discovery expertise and proprietary siRNA technology, which has the potential to enable sustained and precise mRNA silencing. AbbVie will contribute its expertise in antibody engineering, antibody drug conjugates (ADCs) and tissue delivery approaches as appropriate, to augment ADARx's discovery efforts.

AbbVie And ADARx Pharma Announce Collaboration And License Option Agreement To Develop siRNA Therapeutics Across Multiple Disease Areas, Including Neuroscience, Immunology And Oncology

Citigroup analyst Geoff Meacham downgrades AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from Buy to Neutral and lowers the price target from $210 to $205.

Downgrades

Price Target

Citigroup Downgrades AbbVie to Neutral, Lowers Price Target to $205

In the current market session, AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock price is at $188.93, after a 0.60% drop. However, over the past month, the company's stock increased by 6.84%, and in the past year, by 15.33%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747162834_0.png" alt="Past Year Chart" />

<h3>AbbVie P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 44.82 in the Biotechnology industry, AbbVie Inc. has a higher P/E ratio of 81.23. Shareholders might be inclined to think that AbbVie Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747162834_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into AbbVie Inc's Price Over Earnings

AbbVie's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has risen 17.89% since its last report. The company recently reported that it has 19.80 million shares sold short, which is 1.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747148421_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AbbVie has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 6.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About AbbVie?

Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 37%, bearish.
Out of all of the options we uncovered, 7 are puts, for a total amount of $806,471, and there was 1 call, for a total amount of $65,475.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $185.0 for AbbVie over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AbbVie's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AbbVie's substantial trades, within a strike price spectrum from $150.0 to $185.0 over the preceding 30 days.
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747069351_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.9</td>
<td>$0.71</td>
<td>$0.88</td>
<td>$180.00</td>
<td>$440.0K</td>
<td>12.2K</td>
<td>10.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$0.39</td>
<td>$0.08</td>
<td>$0.18</td>
<td>$170.00</td>
<td>$108.0K</td>
<td>11.1K</td>
<td>10.3K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.86</td>
<td>$0.71</td>
<td>$0.88</td>
<td>$180.00</td>
<td>$88.0K</td>
<td>12.2K</td>
<td>10.2K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$43.65</td>
<td>$42.4</td>
<td>$43.65</td>
<td>$150.00</td>
<td>$65.4K</td>
<td>125</td>
<td>0</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$8.7</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$185.00</td>
<td>$56.7K</td>
<td>737</td>
<td>137</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Having examined the options trading patterns of AbbVie, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>With a trading volume of 6,249,708, the price of ABBV is up by 3.85%, reaching $191.72.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 73 days from now.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $219.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for AbbVie, targeting a price of $205. 
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $214. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for AbbVie, targeting a price of $250. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $210. 
&#x2A; An analyst from Guggenheim persists with their Buy rating on AbbVie, maintaining a target price of $216. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

AbbVie Unusual Options Activity

May 9, 2025 records indicate that Representative Jared Moskowitz filed a purchase of AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), valued between $27,027 and $405,000. According to the May filing, the transaction occurred on May 9, 2025.
Currently, AbbVie shares are trading up 2.18% at $188.62.
<h3>What Representative Has Been Trading Recently</h3>
Over the previous three years, Jared Moskowitz conducted 310 trades, totaling more than $633 thousand. The largest of these were in Raymond James Finl and Seacoast Banking stock. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>): $15,001 - $50,000 Sale</li>
<li>NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): $1,001 - $15,000 Purchase</li>
<li>Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>): $1,001 - $15,000 Sale</li>
</ul>
Here's a summary of Jared Moskowitz's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Broadcom</td>
<td>AVGO</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>S</td>
<td>2025-03-11</td>
</tr>
<tr>
<td>NVIDIA</td>
<td>NVDA</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-11</td>
</tr>
<tr>
<td>Broadcom</td>
<td>AVGO</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-03-10</td>
</tr>
<tr>
<td>Broadcom</td>
<td>AVGO</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-03-10</td>
</tr>
<tr>
<td>Elevance Health</td>
<td>ELV</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-03-10</td>
</tr>
</tbody>
</table>
Stay informed on Jared Moskowitz's trades and other members of Congress with our real-time <a href="https://www.benzinga.com/gov-trades/members/jared-moskowitz">government trades tracking tool</a>!
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>The Importance of Congressional Transactions</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Politics

AVGO

NVDA

Congressional Trading Report: Rep. Jared Moskowitz Bought Over $27K In AbbVie Stock

Press Releases

Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc. (ABBV) of a Class Action Lawsuit and an Upcoming Deadline

Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm

Legal

Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc.(ABBV)

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV

AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join – Contact Levi & Korsinsky

AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

AbbVie

Notizie

Ultime notizie per AbbVie (NYSE:ABBV) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO